Signal Pharma to develop new treatments for major diseases

Published: 12-Mar-2012
Research & Development Cardiovascular Pharmaceutical

Aberdeen University spin out will focus on breast cancer, heart failure, diabetes and chronic pain

The University of Aberdeen is working with Scottish entrepreneur Dr Derek Douglas CBE to spin out a company that will develop new drugs to treat breast cancer, heart failure, diabetes and chronic pain.

Signal Pharma will be the first company to be spun out from the University’s Kosterlitz Centre for Therapeutics, which is focused on translating biological innovation into new ways of treating, diagnosing and understanding diseases.

The founders of the company are pharmacology expert Professor Ruth Ross and Dr Iain Greig, a medicinal chemist who helped found another University spin out that is developing drugs to treat rheumatoid arthritis. They have joined forces with cardiologist Professor Michael Frenneaux, and molecular imaging expert Professor Matteo Zanda. Dr Derek Douglas, chairman and ceo of Adam Smith Ltd is providing financial and business acumen, while Dr Michael Wyllie, founder and director Global Pharma Consulting, will provide drug development expertise.

Sigma Pharma will develop a portfolio of four drug discovery projects based on new pathways and targets identified by the University of Aberdeen scientists.

The firm is seeking to raise £1.5m to develop these projects over a period of three years.

Prof Ross, who is also director of the University’s Kosterlitz Centre, said: ‘The creation of Signal Pharma is a great opportunity to generate both medical and economic benefits based on the world class biomedical research of discoveries of the University of Aberdeen.’

Dr Greig added: ‘It is particularly satisfying to see ideas that we have worked on for many years reaching the next stage of the development process, which we hope will eventually lead to new drugs that give real benefits to the patients, saving lives and reducing suffering.’

See more

You may also like

Research & Development

New company created to develop novel technology to treat diabetes

Read more
Islexa technology has the potential to bring islet transplant therapy to treat type 1 diabetes

Trending Articles

  1. From powder to granules: a deep dive into wet granulation methods - WEBINAR NOW ON DEMAND Join ACG in partnership with Manufacturing Chemist for an expert-led session to explore how different wet granulation methods impact consistency, yield, and quality — and what really matters when it comes to selecting and optimising your process
  2. Orphan drug sales to exceed $400bn by 2032, Evaluate report finds Despite FDA policy shifts and the rise of blockbuster obesity drugs, a new Evaluate report confirms rare disease therapies are on track to claim more than a fifth of all global prescription drug sales within a decade
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Atrogi doses first subjects in human trial of exercise-mimicking oral therapy ATR-258 The Swedish biotech has initiated a human trial of ATR-258, a first-in-class oral β2-adrenergic receptor modulator designed to replicate the metabolic effects of exercise, including fat loss and muscle preservation, without the cardiovascular side effects associated with traditional β2-agonists
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist

Upcoming event

Cleanroom Technology Awards 2026

13 April | Virtual See all

You may also like

Research & Development

New company created to develop novel technology to treat diabetes

Islexa technology has the potential to bring islet transplant therapy to treat type 1 diabetes
Research & Development

Aberdeen University wins £5.1m grant to tackle fungal infections

New strategies needed to combat life-threatening invasive fungal infections
Research & Development

Drug discovery centre to open in Aberdeen

Kosterlitz Centre for Therapeutics will take ideas from bench to bedside
Manufacturing

Nulogy launches Supplier Compliance Management to build stronger, more resilient supplier networks

Nulogy, a leading provider of manufacturing operations software, announced the launch of Nulogy Supplier Compliance Management, a solution designed to centralise and automate supplier compliance for procurement, supply chain, and quality assurance teams in manufacturing, food & beverage, pharmaceuticals, and other highly regulated industries
Regulatory

TurboFil debuts latest generation of through-the-tip benchtop syringe filler

TipFil Plus provides precise, aseptic-ready filling and capping for lab and pharmacy applications
Manufacturing

Concentrating recombinant proteins for drug discovery using centrifugal evaporation

Exploring purification, concentration and sample protection in recombinant protein workflows
Research & Development

COVID-19 immunity lowers the risk of a new pandemic

Researchers at the MRC-University of Glasgow Centre for Virus Research have demonstrated that the likelihood of the emergence of a new SARS-type virus pandemic has been significantly reduced by population-wide immunity to SARS-CoV-2
Subscribe now